Edition:
United States

Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

5.35SEK
22 Sep 2017
Change (% chg)

0.30kr (+5.94%)
Prev Close
5.05kr
Open
5.00kr
Day's High
5.40kr
Day's Low
5.00kr
Volume
205,625
Avg. Vol
153,769
52-wk High
21.90kr
52-wk Low
4.15kr

Latest Key Developments (Source: Significant Developments)

Active Biotech Q2 operating loss 23.1 mln SEK
Thursday, 10 Aug 2017 02:30am EDT 

Aug 10 (Reuters) - Active Biotech Ab :Active biotech ab q2 operating loss 23.1 million sek.Active biotech ab q2 sales 5.1 million sek.  Full Article

Active Biotech appoints Helen Tuvesson as new CEO
Monday, 19 Jun 2017 09:30am EDT 

June 19 (Reuters) - Active Biotech Ab :the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB.Tuvesson will take up the position on July 1.Tomas Leanderson, CEO since 2008, will be at the company's disposal during a transitional period.  Full Article

Active Biotech Q4 operating loss narrows to SEK 13.5 mln
Thursday, 16 Feb 2017 02:30am EST 

Active Biotech Ab : Q4 net sales SEK 7.1 million versus SEK 5.0 million year ago . Q4 operating loss SEK 13.5 million versus SEK 28.2 million year ago .Says operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017.  Full Article

Active Biotech to raise SEK 55 mln via rights issue
Monday, 14 Nov 2016 01:28am EST 

Active Biotech Ab : Active biotech carries out rights issue of approximately 55 million Swedish crowns ($6.03 million) . Says subscription price amounts to 8 crowns per share . Says shareholders of the company have pre-emptive rights to subscribe for the new shares, whereby 13 existing shares entitle to subscription for one new share. Subscription for shares in the rights issue can only be made with pre-emptive rights . Subscription shall be made during the period 23 November - 7 December 2016 . Says rights issue is at no cost guaranteed in its entirety by Active Biotech's largest shareholder MGA Holding AB . The rights issue that now is conducted aims at providing Active Biotech with the financial stability required to await the outcome of the ongoing phase 3 study of laquinimod for the treatment of RRMS and the phase 2 study for the treatment of PPMS . If the outcome of these studies is positive, the Company expects that a positive operating result can be achieved from and including the financial year 2018 .Says proceeds from the rights issue, approximately SEK 55 million at full subscription, are intended to be used mainly for general working capital requirements.  Full Article

Active Biotech Q3 loss narrows
Monday, 14 Nov 2016 01:20am EST 

Active Biotech Ab : Active biotech AB interim report January - September 2016 . Q3 net sales SEK 4.1 million (5.2 mln) . Q3 operating loss SEK 11.1 million (loss of 22.2 mln) .Cash and cash equivalents at the end of the period SEK 39.9 million.  Full Article

Active Biotech AB says no dividend would be paid
Friday, 27 May 2016 02:33am EDT 

Active Biotech Ab : Annual general meeting of active biotech ab . In accordance with board of directors' proposal, it was resolved that no dividend would be paid .Board members and managing director were discharged from liability with respect to their management of company for 2015.  Full Article

Active Biotech plans to develop tasquinimod for treatment of multiple myeloma
Wednesday, 23 Mar 2016 03:40am EDT 

Active Biotech AB:Plans to develop tasquinimod for the treatment of multiple myeloma.Says patent application for the treatment of multiple myeloma with the company's compound tasquinimod will be public within short.Says with this application, treatment of multiple myeloma with tasquinimod is potentially protected until 2035.Preclinical program was performed and very good results were achieved in models for multiple myeloma.Says will actively seek a collaboration partner for the development of tasquinimod within this indication.During 2016 orphan drug status applications for tasquinimod treatment of multiple myeloma are planned to be submitted to authorities in the EU and USA.Multiple myeloma is an incurable form of blood cancer where the plasma cells in the bone marrow grow uncontrollably while other blood forming cells such as white and red blood cells and blood platelets are suppressed.Says total market for multiple myeloma drugs amounted to 7.8 billion usd in 2013 (globaldata 2015).  Full Article

Active Biotech says stops higher doses MS trials of Laquinimod
Monday, 4 Jan 2016 09:01am EST 

Active Biotech AB:Says Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials.Says ‍occurrence of cardiovascular events, none of which was fatal, in eight patients​.Says ‍both trials, concerto and arpeggio, are continuing lower-dose arms (0.6mg daily), and participants in trials will be provided with an update to confirm re-consent for participation​.  Full Article

BRIEF-Active Biotech Q2 operating loss 23.1 mln SEK

* Active biotech ab q2 sales 5.1 million sek Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)